View Press Releases
-
BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing
VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development.
Sep 19, 2022
-
Integrated DNA Technologies Expands Customization Options for Alt-R™ Custom CRISPR gRNA Libraries for Drug Discovery
-
Inizio Biotech makes key leadership appointment to meet demand from emerging biotech
-
Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies
-
TFDA Grants CTL Amedica License to Market MATISSE™ ACIF Cage System
The Taiwan Food and Drug Administration has granted CTL Amedica Corporation a license to market the MATISSE Anterior Cervical Interbody Fusion (ACIF) Cage System.
Sep 14, 2022
-
Clinion - Platinum Sponsor for ISCR 3rd Autumn Conference 2022
-
BrightInsight Selects Lyniate to Enhance Interoperability Strategic Engagement Will Improve Information Exchange for Regulated Digital Health Solutions Built on the BrightInsight® Platform
-
Graphene Modification Helps to Unlock New Potentials
-
Accelerated Shelf-Life Testing to Assess Drug Stability
-
Four Most Commonly Used Surfactants You Should Know
-
Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
-
BioIVT Acquires XenoTech, a Leading Provider of Products and Services for Preclinical Testing of New Drug Candidates
XenoTech specializes in providing ADME-Tox products and research services, in particular drug metabolism and pharmacokinetics (DMPK) and drug-drug interaction (DDI) studies.
Sep 11, 2022
-
Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery
Molecular Devices and HeartBeat.bio AG have entered into a co-development agreement to commercialize a first-of-its-kind automated offering that will enable researchers to reliably scale production of Cardioids and advance cardiac drug discovery.
Sep 11, 2022
-
BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies.
Sep 11, 2022
-
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
-
DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program
DNAnexus awarded a 3-year contract by Our Future Health to provide a scalable, cloud-based trusted research environment for the large-scale population research program that aims to recruit up to 5 million volunteers. Approved researchers from the global life sciences, healthcare, and academic communities will be able to use the DNAnexus platform to securely explore and analyze the de-identified data.
Sep 11, 2022
-
BOC Sciences August Promotion: Comprehensive Labeled Peptides with Stable Quality
As a pioneer in stable isotopic labeling chemistry, BOC Sciences develops a large variety of SIL compounds. Its promotion of labeled peptides, the increasingly used materials for convenient detection in research, is on the boil in August.
Sep 11, 2022
-
BOC Sciences 2022 Free Webinar: Viral RNA Modifications and Implications for Novel Therapeutics
BOC Sciences grandly announced the schedule of a free webinar on September 19th, 2022, at 11:00 EDT, which is a laudable event centering on the hot spot of RNA research during the pandemic.
Sep 11, 2022
-
BOC Sciences August Promotion: Compound Docking Solutions for Drug Discovery
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets.
Sep 11, 2022
-
BioIVT Highlights ADME-Tox Research Advances at ISSX/MDO 2022
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
Sep 8, 2022